IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP
Vulvar, Vaginal, Penile, Rectal Cancer
National Cancer Institute (NCI)protein_peptidePhase 1/2Active
CCC
55/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Vulvar, Vaginal, Penile, Rectal Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
pds0101 National Cancer Institute (NCI) | Phase 1/2 | CCC |
Epinephrine National Cancer Institute (NCI) | Phase 1/2 | CCC |
IBUPROFEN National Cancer Institute (NCI) | Phase 1/2 | CCC |
Benadryl National Cancer Institute (NCI) | Phase 1/2 | CCC |
Prgn-2009 National Cancer Institute (NCI) | Phase 1/2 | CCC |
DEXAMETHASONE National Cancer Institute (NCI) | Phase 1/2 | CCC |
Immunocytokine Nhs-Il12 National Cancer Institute (NCI) | Phase 1/2 | CC |
Same molecule, other indications
IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →